Skip to main content
. Author manuscript; available in PMC: 2021 Feb 4.
Published in final edited form as: Oncogene. 2020 Aug 4;39(37):5979–5994. doi: 10.1038/s41388-020-01410-z

Figure 5. IMPAD1 and KDELR2 localize to the ER-Golgi pathway.

Figure 5.

a. Co-immunofluorescence for human IMPAD1 (red) and Golgi marker, GM130 (green) in 393P cells with IMPAD1 overexpression. Nucleus was stained with Dapi. Cells were treated with DMSO (upper) or Brefeldin-A (BFA) at 1uM for 4 hours (lower). IMPAD1 localization to the Golgi is disrupted upon BFA treatment, which abrogates Golgi stacking. b-i. Co-immunofluorescence for FLAG-KDELR2 (red) and Calnexin (green) in 393P cells with mouse KDELR2 overexpression or empty vector control. Cells were treated with DMSO (upper) or Brefeldin-A (1uM 4 hours) (lower). b-ii. Co-immunofluorescence for FLAG-KDELR2 (red) and GM130 (green) in 393P cells with KDELR2 overexpression or empty vector control. Cells were treated with DMSO (upper) or Brefeldin-A (1uM 4 hours) (lower). Nucleus was stained with DAPI. Scale bar for all images:10uM. See also Supplemental Fig. S8.